Showing results (241-250 of 276) with videos related to
Sort By:
Pageof 28
American Heart Journal|October 31, 2000
Valsartan in acute myocardial infarction trial (VALIANT): rationale and designM A Pfeffer, J McMurray, A Leizorovicz, et al.European Heart Journal|June 19, 2002
Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-IIE M Antman, H A Cooper, C M Gibson, et al.Journal of the American College of Cardiology|September 19, 1998
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary ArteriesM Pfisterer, J L Cox, C B Granger, et al.The New England Journal of Medicine|March 16, 2000
Cost effectiveness of early discharge after uncomplicated acute myocardial infarctionL K Newby, E L Eisenstein, R M Califf, et al.The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.Circulation|February 22, 2001
Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studiesG I Barbash, Y Birnbaum, K Bogaerts, et al.European Heart Journal|December 1, 2001
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PAF Van de Werf, H V Barron, P W Armstrong, et al.European Journal of Nuclear Medicine|February 1, 1995
Metabolism of nitrogen-13 labelled ammonia in different conditions in dogs, human volunteers and transplant patientsG Bormans, A Maes, W Langendries, et al.Circulation|June 20, 2001
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudyL K Newby, E M Ohman, R H Christenson, et al.Circulation|August 16, 2000
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic diseaseR A Harrington, P W Armstrong, C Graffagnino, et al.Pageof 28